Notice of Change to RFA-DA-15-008 "The National Drug Abuse Treatment Clinical Trials Network (UG1)"

Notice Number: NOT-DA-14-018

Key Dates
Release Date: June 29, 2014

Related Announcements
RFA-DA-15-008

Issued by
National Institute on Drug Abuse (NIDA)

Purpose

The National Institute on Drug Abuse (NIDA) is changing Part 2, Section I of RFA-DA-15-008 "The National Drug Abuse Treatment Clinical Trials Network (UG1)" to reference additional background now available in a recently published article.

Part 2, Section I currently reads:
Part 2. Full Text of Announcement
Section I. Funding Opportunity Description

Purpose and Background

This Funding Opportunity Announcement (FOA) invites applications from clinical investigators to participate in the National Drug Abuse Treatment Clinical Trials Network (CTN). This FOA is the seventh solicitation for participation in the CTN. NIDA intends to continue to develop and test interventions for the management of the wide spectrum of substance use problems via collaborative partnerships with an expansive range of clinical research investigators, healthcare providers and institutions.

The CTN was established in 1999 to improve addiction treatment using science as the vehicle and was the first network to bring SUD scientists and providers together in an alliance fostering bi-directional communication and collaboration to improve the relevance of treatment research to clinical practice. The CTN is administered within NIDA through the Center for the Clinical Trials Network (CCTN). The CCTN recognizes a need to develop and test substance use disorder (SUD) management options not only for specialty care settings but also for application in a range of general medical settings. Therefore, the purpose of this FOA is to build on the program of research previously conducted in the CTN (http://www.drugabuse.gov/about-nida/organization/cctn/ctn) and expand its scope to include organizations and/or practice based research networks that offer access to large patient populations, practicing clinicians who are interested in engaging in research, and using digitized health records that are amenable to research data collection. The CTN will be a clinical research enterprise in which a variety of SUD service providers, treatment researchers, participating patients and NIDA cooperatively develop and conduct practical trials answering important research questions that, once answered, will impact practice in a wide variety of settings.

This section is now modified to read:

Purpose and Background

This Funding Opportunity Announcement (FOA) invites applications from clinical investigators to participate in the National Drug Abuse Treatment Clinical Trials Network (CTN).  This FOA is the seventh solicitation for participation in the CTN.  NIDA intends to continue to develop and test interventions for the management of the wide spectrum of substance use problems via collaborative partnerships with an expansive range of clinical research investigators, healthcare providers and institutions.

The CTN was established in 1999 to improve addiction treatment using science as the vehicle and was the first network to bring SUD scientists and providers together in an alliance fostering bi-directional communication and collaboration to improve the relevance of treatment research to clinical practice.  The CTN is administered within NIDA through the Center for the Clinical Trials Network (CCTN).  The CCTN recognizes a need to develop and test substance use disorder (SUD) management options not only for specialty care settings but also for application in a range of general medical settings.  Therefore, the purpose of this FOA is to build on the program of research previously conducted in the CTN (http://www.drugabuse.gov/about-nida/organization/cctn/ctn) and expand its scope to include organizations and/or practice based research networks that offer access to large patient populations, practicing clinicians who are interested in engaging in research, and using digitized health records that are amenable to research data collection.  The CTN will be a clinical research enterprise in which a variety of SUD service providers, treatment researchers, participating patients and NIDA cooperatively develop and conduct practical trials answering important research questions that, once answered, will impact practice in a wide variety of settings. The future of the CTN is further discussed in the article entitled "Expanding the National Drug Abuse Treatment Clinical Trials Network to address the management of substance use disorders in general medical settings" which can be accessed here: http://www.dovepress.com/articles.php?article_id=17711.

All other aspects of the RFA remain the same.

Inquiries

Please direct all inquiries to:

Betty Tai, Ph.D.
National Institute on Drug Abuse (NIDA)
Telephone: 301-443-6397
Email: btai@mail.nih.gov